A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection
Status:
Completed
Trial end date:
2017-05-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether 24 weeks of Daclatasvir and Sofosbuvir with
Ribavirin is safe and effective in the treatment of genotype 3 hepatitis C infected patients
with liver cirrhosis.